Cited by 360Drug Transport and Resistance MechanismsLiver physiology and pathologyWnt/β-catenin signaling in development and cancer

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.

Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice

Open access

Kim, Insook, Morimura, Keiichirou, Shah, Yatrik, Yang, Qian, Ward, Jerrold M., Gonzalez, Frank J.·2007·Carcinogenesis

DOI 10.1093/carcin/bgl249PMC PMC1858639

Open this paper in CoChat — free account Open PDF

Abstract

The farnesoid X receptor (FXR) controls the synthesis and transport of bile acids (BAs). Mice lacking expression of FXR, designated Fxr-null, have elevated levels of serum and hepatic BAs and an increase in BA pool size. Surprisingly, at 12 months of age, male and female Fxr-null mice had a high incidence of degenerative hepatic lesions, altered cell foci and liver tumors including hepatocellular adenoma, carcinoma and hepatocholangiocellular carcinoma, the latter of which is rarely observed in mice. At 3 months, Fxr-null mice had increased expression of the proinflammatory cytokine IL-1beta mRNA and elevated beta-catenin and its target gene c-myc. They also had increased cell proliferation as revealed by increased PCNA mRNA and BrdU incorporation. These studies reveal a potential role for FXR and BAs in hepatocarcinogenesis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/carcin/bgl249

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Self-citation
In situ detection of fragmented DNA (tunel assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: A cautionary note*1
Kraupp, B. G., Ruttkay-Nedecký, B., Koudelka, H., Bukowska, K., Bursch, W., & Schulte‐Hermann, R. (1995) · Hepatology · doi:10.1002/hep.1840210534 · Cited by 1,223
Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice
Zhang, Y., Lee, F. Y., Barrera, G., Lee, H., Vales, C., Gonzalez, F. J., Willson, T. M., & Edwards, P. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506982103 · Cited by 974
Self-citation
Nuclear Receptor-Dependent Bile Acid Signaling Is Required for Normal Liver Regeneration
Huang, W., Ma, K., Zhang, J., Qatanani, M., Cuvillier, J., Liu, J., Dong, B., Huang, X., & Moore, D. D. (2006) · Science · doi:10.1126/science.1121435 · Cited by 645
Endocrine functions of bile acids
Houten, S. M., 渡辺, 光., & Auwerx, J. H. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601049 · Cited by 595
The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice
Cariou, B., van Harmelen, K., Durán-Sandoval, D., van Dijk, T. H., Grefhorst, A., Abdelkarim, M., Caron, S., Torpier, G., Fruchart, J., Gonzalez, F. J., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510258200 · Cited by 546
Self-citation
Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas
Faubion, W. A., Guicciardi, M. E., Miyoshi, H., Bronk, S. F., Roberts, P. J., Svingen, P. A., Kaufmann, S. H., & Gores, G. J. (1999) · Journal of Clinical Investigation · doi:10.1172/jci4765 · Cited by 539
The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis
Fiorucci, S., Antonelli, E., Rizzo, G., Renga, B., Mencarelli, A., Riccardi, L., Orlandi, S., Pellicciari, R., & Morelli, A. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.08.001 · Cited by 472
Activation of hepatic stellate cells - a key issue in liver fibrosis
Reeves, H. L. (2002) · Frontiers in bioscience · doi:10.2741/reeves · Cited by 421
Reduction and enhancement by phenobarbital of hepatocarcinogenesis induced in the rat by 2-acetylaminofluorene.
Peraino, C., Fry, R. J., & Staffeldt, E. F. (1971) · PubMed · Cited by 410

Flagged first, then by citations

Show all 38 references

1 of the 38 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Haseman, 1999, Chapter 26, Neoplasm Incidences in B6C3F1 Mice: NTP Historical Data

Sorted by citations

Items 101–200 of 360

Farnesoid X receptor, overexpressed in pancreatic cancer with lymph node metastasis promotes cell migration and invasion
Lee, J. Y., Lee, J. K., Lee, J. K., Lee, K. H., Jang, K.-T., Heo, J. S., Choi, S. H., Kim, Y., & Rhee, P. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.37 · Cited by 76
Regulation of bile acid receptor activity
Wan, Y. Y., & Sheng, L. (2018) · Liver Research · doi:10.1016/j.livres.2018.09.008 · Cited by 75
Suppression of Autophagic Flux by Bile Acids in Hepatocytes
Manley, S., Ni, H., Kong, B., Apte, U. M., Guo, G. L., & Ding, W. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft246 · Cited by 71
Intracellular signaling and hepatocellular carcinoma
Iakova, P. A., Timchenko, L., & Timchenko, N. A. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.09.001 · Cited by 71
Bile acids promote diethylnitrosamine-induced hepatocellular carcinoma via increased inflammatory signaling
Sun, L., Beggs, K. M., Borude, P. C., Edwards, G., Bhushan, B., Walesky, C. M., Roy, N., Manley, M. W., Gunewardena, S., O’Neil, M. F., et al. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00027.2015 · Cited by 70
Senescent hepatic stellate cells caused by deoxycholic acid modulates malignant behavior of hepatocellular carcinoma
Nguyen, P. T., Kanno, K., Phạm, Q. T., Kikuchi, Y. S., Kakimoto, M., Kobayashi, T., Otani, Y., Kishikawa, N., Miyauchi, M., Arihiro, K., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03374-9 · Cited by 70
The role of transketolase in human cancer progression and therapy
Hao, S., Meng, Q., Sun, H., Li, Y., Li, Y., Gu, L., Liu, B., Zhang, Y., Zhou, H., Xu, Z., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113607 · Cited by 70
Targeting Farnesoid X receptor (FXR) for developing novel therapeutics against cancer
Girisa, S., Henamayee, S., Parama, D., Rana, V., Dutta, U., & Kunnumakkara, A. B. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00035-2 · Cited by 67
The Hippo signaling pathway in liver regeneration and tumorigenesis
Hong, L., Cai, Y., Jiang, M., Zhou, D., & Chen, L. (2014) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmu106 · Cited by 68
A tea catechin, epigallocatechin-3-gallate, is a unique modulator of the farnesoid X receptor
Li, G., Lin, W., Araya, J. J., Chen, T., Timmermann, B. N., & Guo, G. L. (2011) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2011.11.006 · Cited by 65
Obeticholic acid for the treatment of primary biliary cirrhosis
Trivedi, P. J., Hirschfield, G. M., & Gershwin, M. E. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1092381 · Cited by 66
Conformationally constrained farnesoid X receptor (FXR) agonists: Heteroaryl replacements of the naphthalene
Bass, J. Y., Caravella, J. A., Chen, L., Creech, K. L., Deaton, D. N., Madauss, K. P., Marr, H. B., McFadyen, R. B., Miller, A. B., Mills, W. Y., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.089 · Cited by 60
Genome-Wide Binding and Transcriptome Analysis of Human Farnesoid X Receptor in Primary Human Hepatocytes
Zhan, L., Liu, H.-X., Fang, Y., Kong, B., He, Y.-Q., Zhong, X.-B., Fang, J.-W., Wan, Y., & Guo, G. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105930 · Cited by 62
Farnesoid X receptor regulates forkhead Box O3a activation in ethanol-induced autophagy and hepatotoxicity
Manley, S., Ni, H., Williams, J. A. R., Kong, B., DiTacchio, L., Guo, G. L., & Ding, W. (2014) · Redox Biology · doi:10.1016/j.redox.2014.08.007 · Cited by 61
Synbiotics Bifidobacterium infantis and milk oligosaccharides are effective in reversing cancer-prone nonalcoholic steatohepatitis using western diet-fed FXR knockout mouse models
Jena, P. K., Sheng, L., Nagar, N., Wu, C., Barile, D., Mills, D. A., & Wan, Y.-J. Y. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.04.007 · Cited by 60
Pharmacological agents for NASH
Ratziu, V. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.193 · Cited by 59
Targeting the FGF19–FGFR4 pathway for cholestatic, metabolic, and cancerous diseases
Li, X., Lu, W., Kharitonenkov, A., & Luo, Y. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13767 · Cited by 64
Reciprocal regulation of the bile acid-activated receptor FXR and the interferon-γ-STAT-1 pathway in macrophages
Renga, B., Migliorati, M., Mencarelli, A., & Fiorucci, S. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.04.004 · Cited by 60
The hippo pathway: A master regulator of liver metabolism, regeneration, and disease
Nguyen‐Lefebvre, A. T., Selzner, N., Wrana, J. L., & Bhat, M. (2021) · The FASEB Journal · doi:10.1096/fj.202002284rr · Cited by 58
The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis
Cariou, B. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)74605-6 · Cited by 58
Activation of the nuclear receptor FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against genotoxic compounds
Vaquero, J., Briz, Ó., Herráez, E., Muntané, J., & Marı́n, J. J. G. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.05.006 · Cited by 62
The nuclear translocation of transketolase inhibits the farnesoid receptor expression by promoting the binding of HDAC3 to FXR promoter in hepatocellular carcinoma cell lines
Li, M., Zhang, X., Lu, Y., Meng, S., Quan, H., Hou, P., Tong, P., Chai, D., Gao, X., Zheng, J., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2225-6 · Cited by 60
Cross-talk between bile acids and gastrointestinal tract for progression and development of cancer and its therapeutic implications
Kundu, S., Kumar, S., & Bajaj, A. (2015) · IUBMB Life · doi:10.1002/iub.1399 · Cited by 56
Nuclear bile acid receptor FXR in the hepatic regeneration
Chen, W., Wang, Y., Meng, Z., Zhang, L., & Huang, W. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.12.006 · Cited by 58
Exploring the abomasal lymph node transcriptome for genes associated with resistance to the sheep nematode Teladorsagia circumcincta
Gossner, A. G., Wilkie, H., Joshi, A., & Hopkins, J. (2013) · Veterinary Research · doi:10.1186/1297-9716-44-68 · Cited by 64
Tissue and serum metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma
Han, J. S., Qin, W., Li, Z., Xu, A., Xing, H., Wu, H., Zhang, H., Wang, M.-D., Li, C., Liang, L., et al. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.10.039 · Cited by 55
Med1 Subunit of the Mediator Complex in Nuclear Receptor-Regulated Energy Metabolism, Liver Regeneration, and Hepatocarcinogenesis
Jia, Y., Viswakarma, N., & Reddy, J. K. (2014) · Gene Expression · doi:10.3727/105221614x13919976902219 · Cited by 54
Mutations in the C-terminus of the X protein of hepatitis B virus regulate Wnt-5a expression in hepatoma Huh7 cells: cDNA microarray and proteomic analyses
Liu, X., Wang, L., Zhang, S., Lin, J., Zhang, S., Feitelson, M. A., Gao, H., & Zhu, M.-H. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn111 · Cited by 57
Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis
Gadaleta, R. M., Scialpi, N., Peres, C. M., Cariello, M., Ko, B., Luo, J., Porru, E., Roda, A., Sabbà, C., & Moschetta, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-35496-z · Cited by 54
The pathophysiological function of non-gastrointestinal farnesoid X receptor
Yan, N., Yan, T., Xia, Y., Hao, H., Wang, G., & Gonzalez, F. J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107867 · Cited by 56
Self-citation
Endogenous bile acids as carcinogens
Jansen, P. L. M. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.06.001 · Cited by 52
Fibroblast Growth Factor 15–Dependent and Bile Acid–Independent Promotion of Liver Regeneration in Mice
Kong, B., Sun, R., Huang, M., Chow, M. D., Zhong, X., Xie, W., Lee, Y., & Guo, G. L. (2018) · Hepatology · doi:10.1002/hep.30041 · Cited by 52
Evolution of Genomic Instability in Diethylnitrosamine-Induced Hepatocarcinogenesis in Mice Δ
Aleksic, K., Lackner, C., Geigl, J. B., Schwarz, M., Auer, M., Ulz, P., Fischer, M., Trajanoski, Z., Otte, M., & Speicher, M. R. (2010) · Hepatology · doi:10.1002/hep.24133 · Cited by 52
FXR induces SOCS3 and suppresses hepatocellular carcinoma
Guo, F., Xu, Z., Zhang, Y., Jiang, P., Huang, G., Chen, S., Lyu, X., Zheng, P., Zhao, X., Zeng, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5314 · Cited by 50
Beyond Bile Acids: Targeting Farnesoid X Receptor (FXR) with Natural and Synthetic Ligands
Carotti, A., Marinozzi, M., Custodi, C., Cerra, B., Pellicciari, R., Gioiello, A., & Macchiarulo, A. (2014) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026614666141112094058 · Cited by 50
Waltonitone inhibits proliferation of hepatoma cells and tumorigenesis via FXR-miR-22-CCNA2 signaling pathway
Yang, F., Gong, J., Wang, G., Chen, P., Yang, L., & Wang, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.12614 · Cited by 50
Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury
Petrescu, A. D., & DeMorrow, S. (2021) · Cells · doi:10.3390/cells10081846 · Cited by 48
Circulating Bile Acids as Biomarkers for Disease Diagnosis and Prevention
Li, Q., & Chen, Y. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac659 · Cited by 51
Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice
Li, G., Kong, B., Zhu, Y., Zhan, L., Williams, J. A. R., Tawfik, O. W., Kassel, K. M., Luyendyk, J. P., Wang, L., & Guo, G. L. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.06.016 · Cited by 49
Aldo-keto reductase 1B7 is a target gene of FXR and regulates lipid and glucose homeostasis
Ge, X., Yin, L., Ma, H., Li, T., Chiang, J. Y. L., & Zhang, Y. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m015859 · Cited by 49
Mice with hepatocyte-specific FXR deficiency are resistant to spontaneous but susceptible to cholic acid-induced hepatocarcinogenesis
Kong, B., Zhu, Y., Li, G., Williams, J. A. R., Buckley, K., Tawfik, O. W., Luyendyk, J. P., & Guo, G. L. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00134.2015 · Cited by 50
Farnesoid X Receptor Activation Enhances Transforming Growth Factor β-Induced Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma Cells
Kainuma, M., Takada, I., Makishima, M., & Sano, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071898 · Cited by 49
Farnesoid X receptor agonists for primary biliary cirrhosis
Lindor, K. D. (2011) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32834452c8 · Cited by 48
Nuclear receptors in regenerating liver and hepatocellular carcinoma
Vacca, M., Degirolamo, C., Massafra, V., Polimeno, L., Mariani‐Costantini, R., Palasciano, G., & Moschetta, A. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.06.025 · Cited by 49
Oral benzo[a]pyrene‐induced cancer: Two distinct types in different target organs depend on the mouseCyp1genotype
Shi, Z., Dragin, N., Miller, M. L., Stringer, K. F., Johansson, E., Chen, J., Uno, S., Gonzalez, F. J., Rubio‐Terres, C., & Nebert, D. W. (2010) · International Journal of Cancer · doi:10.1002/ijc.25222 · Cited by 50
Self-citation
Unifying Mechanisms of Action of the Anticancer Activities of Triterpenoids and Synthetic Analogs
Safe, S. H., Prather, P. L., Brents, L. K., Chadalapaka, G., & Jutooru, I. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012803833099 · Cited by 47
Role of Farnesoid X Receptor and Bile Acids in Hepatic Tumor Development
Takahashi, S., Tanaka, N., Fukami, T., Xie, C., Yagai, T., Kim, D., Velenosi, T. J., Yan, T., Krausz, K. W., Levi, M., et al. (2018) · Hepatology Communications · doi:10.1002/hep4.1263 · Cited by 49
Self-citation
Zonation in NASH – A key paradigm for understanding pathophysiology and clinical outcomes
Steinman, J. B., Salomao, M. A., & Pajvani, U. B. (2021) · Liver International · doi:10.1111/liv.15025 · Cited by 49
Identification of Mitochondrial-Related Prognostic Biomarkers Associated With Primary Bile Acid Biosynthesis and Tumor Microenvironment of Hepatocellular Carcinoma
Zhang, T., Nie, Y., Gu, J., Cai, K., Chen, X., Li, H., & Wang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.587479 · Cited by 43
Farnesoid X Receptor Antagonizes JNK Signaling Pathway in Liver Carcinogenesis by Activating SOD3
Wang, Y., Chen, W., Li, C., Guo, C., Li, Y., Qi, H. M., Shen, H., Kong, J., Long, X., Yuan, F., et al. (2014) · Molecular Endocrinology · doi:10.1210/me.2014-1225 · Cited by 46
Bile Acid-Induced Elevated Oxidative Stress in the Absence of Farnesoid X Receptor
Nomoto, M., Miyata, M., Yin, S.-A., Kurata, Y., Shimada, M., Yoshinari, K., Gonzalez, F. J., Suzuki, K., Shibasaki, S., Kurosawa, T., et al. (2009) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.32.172 · Cited by 45
Self-citation
The emerging role of bile acids as critical components in nanotechnology and bioengineering: Pharmacology, formulation optimizers and hydrogel-biomaterial applications
Kovačević, B., Jones, M., Ionescu, C. M., Walker, D., Wagle, S. R., Chester, J., Foster, T., Brown, D. J., Mikov, M., Mooranian, A., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121459 · Cited by 46
Hepatocyte Nuclear Factor 4 Alpha and Farnesoid X Receptor Co-regulates Gene Transcription in Mouse Livers on a Genome-Wide Scale
Thomas, A., Hart, S. N., Li, G., Lü, H., Fang, Y., Fang, J., Zhong, X., & Guo, G. L. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1006-7 · Cited by 45
Novel bile acid therapeutics for the treatment of chronic liver diseases
Hegade, V. S., Speight, A., Etherington, R. E., & Jones, D. E. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16630712 · Cited by 44
Long-term Administration of Nuclear Bile Acid Receptor FXR Agonist Prevents Spontaneous Hepatocarcinogenesis in Abcb4−/− Mice
Cariello, M., Peres, C., Zerlotin, R., Porru, E., Sabbà, C., Roda, A., & Moschetta, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-11549-7 · Cited by 39
Obeticholic Acid Ameliorates Valproic Acid–Induced Hepatic Steatosis and Oxidative Stress
Gai, Z., Krajnc, E., Samodelov, S. L., Visentin, M., & Kullak-Ublick, G. A. (2020) · Molecular Pharmacology · doi:10.1124/mol.119.118646 · Cited by 44
Protein and Steroid Profiles in Follicular Fluid after Ovarian Hyperstimulation as Potential Biomarkers of IVF Outcome
Kushnir, M. M., Naessén, T., Wånggren, K., Rockwood, A. L., Crockett, D. K., & Bergquist, J. (2012) · Journal of Proteome Research · doi:10.1021/pr300535g · Cited by 44
Cholestasis-induced bile acid elevates estrogen level via farnesoid X receptor–mediated suppression of the estrogen sulfotransferase SULT1E1
Liu, X., Xue, R., Yang, C., Gu, J., Chen, S., & Zhang, S. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.001789 · Cited by 45
FXR protects lung from lipopolysaccharide-induced acute injury.
Zhang, L.-S., Li, T., Yu, D. D., Forman, B. M., & Huang, W.-D. (2012) · Molecular Endocrinology · doi:10.1210/me.2011-0042 · Cited by 39
Molecular Targets in Hepatocarcinogenesis and Implications for Therapy
Wu, M., Yiang, G.-T., Cheng, P., Chu, P., & Li, C. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080213 · Cited by 43
Expression of SLCO1B3 is associated with intratumoral cholestasis and CTNNB1 mutations in hepatocellular carcinoma
Sekine, S., Ogawa, R., Ojima, H., & Kanai, Y. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01990.x · Cited by 42
Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-κB: New insights into hepatic inflammation
Wagner, M., Zollner, G., & Trauner, M. (2008) · Hepatology · doi:10.1002/hep.22668 · Cited by 40
Farnesoid X receptor associates with β-catenin and inhibits its activity in hepatocellular carcinoma
Liu, X., Zhang, X., Ji, L., Gu, J., Zhou, M., & Chen, S. (2015) · Oncotarget · doi:10.18632/oncotarget.2899 · Cited by 40
Bile Acids Conjugation in Human Bile Is Not Random: New Insights from 1 H‐NMR Spectroscopy at 800 MHz
Gowda, G. A. N., Shanaiah, N., Cooper, A. B., Maluccio, M. A., & Raftery, D. (2009) · Lipids · doi:10.1007/s11745-009-3296-4 · Cited by 39
Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease
Halilbasic, E., Fuchs, C. D., Traussnigg, S., & Trauner, M. (2016) · Digestive Diseases · doi:10.1159/000445268 · Cited by 39
Steroidal Scaffolds as FXR and GPBAR1 Ligands: From Chemistry to Therapeutical Application
Sepe, V., Distrutti, E., Limongelli, V., Fiorucci, S., & Zampella, A. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.54 · Cited by 37
microRNA-192 suppresses the expression of the farnesoid X receptor
Krattinger, R., Boström, A. E. D., Schiöth, H. B., Thasler, W. E., Mwinyi, J., & Kullak-Ublick, G. A. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00297.2015 · Cited by 39
The altered lipidome of hepatocellular carcinoma
Tan, S. L. W., Israeli, E., Ericksen, R. E., Chow, P. K. H., & Han, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.004 · Cited by 37
Mechanistic insights into isoform-dependent and species-specific regulation of bile salt export pump by farnesoid X receptor
Song, X., Chen, Y., Valanejad, L., Kaimal, R., Yan, B., Stoner, M. A., & Deng, R. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m038323 · Cited by 38
Bile acids as drivers and biomarkers of hepatocellular carcinoma
Colosimo, S., & Tomlinson, J. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i9.1730 · Cited by 38
Nuclear receptors and the Warburg effect in cancer
Thorne, J. L., & Campbell, M. J. (2014) · International Journal of Cancer · doi:10.1002/ijc.29012 · Cited by 36
Disrupting bile acid metabolism by suppressing Fxr causes hepatocellular carcinoma induced by YAP activation
Liu, Y., Zhu, J., Jin, Y., Sun, Z., Wu, X., Zhou, H., & Yang, Y. (2025) · Nature Communications · doi:10.1038/s41467-025-58809-z · Cited by 36
Conformationally constrained farnesoid X receptor (FXR) agonists: Alternative replacements of the stilbene
Akwabi-Ameyaw, A., Caravella, J. A., Chen, L., Creech, K. L., Deaton, D. N., Madauss, K. P., Marr, H. B., Miller, A. B., Navas, F., Parks, D. J., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.08.034 · Cited by 37
Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies
Snyder, H. S., Sakaan, S. A., March, K. L., Siddique, O., Cholankeril, R. T., Cummings, C. D., Gadiparthi, C., Satapathy, S. K., Ahmed, A., & Cholankeril, G. T. (2018) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00050 · Cited by 37
The Role of Thymine DNA Glycosylase in Transcription, Active DNA Demethylation, and Cancer
Onabote, O., Hassan, H. M., Isovic, M., & Torchia, J. (2022) · Cancers · doi:10.3390/cancers14030765 · Cited by 38
Farnesoid X receptor ablation sensitizes mice to hepatitis b virus X protein–induced hepatocarcinogenesis
Niu, Y., Xu, M., Slagle, B. L., Huang, H., Li, S., Guo, G. L., Shi, G., Qin, W., & Xie, W. (2016) · Hepatology · doi:10.1002/hep.28924 · Cited by 35
FXR Acts as a Metastasis Suppressor in Intrahepatic Cholangiocarcinoma by Inhibiting IL-6-Induced Epithelial-Mesenchymal Transition
Lv, B., Ma, L., Tang, W.-Q., Huang, P.-X., Yang, B.-W., Wang, L.-X., Chen, S., Gao, Q., Zhang, S., & Xia, J. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000491715 · Cited by 31
Taurine attenuates hepatic steatosis in a genetic model of fatty liver disease
Miyata, M., Funaki, A., Fukuhara, C., Sumiya, Y., & Sugiura, Y. (2020) · The Journal of Toxicological Sciences · doi:10.2131/jts.45.87 · Cited by 34
Hepatocyte‐specific deletion of Cdc42 results in delayed liver regeneration after partial hepatectomy in mice†
Yuan, H., Zhang, H., Wu, X., Zhang, Z., Du, D., Zhou, W., Zhou, S., Brakebusch, C., & Chen, Z. (2008) · Hepatology · doi:10.1002/hep.22610 · Cited by 34
Tissue Specific Induction of p62/Sqstm1 by Farnesoid X Receptor
Williams, J. A. R., Thomas, A., Li, G., Kong, B., Zhan, L., Inaba, Y., Xie, W., Ding, W., & Guo, G. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043961 · Cited by 33
Synergistic growth inhibition of human hepatocellular carcinoma cells by acyclic retinoid and GW4064, a farnesoid X receptor ligand
Ohno, T., Shirakami, Y., Shimizu, M., Kubota, M., Sakai, H., Yasuda, Y., Kochi, T., Tsurumi, H., & Moriwaki, H. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.04.015 · Cited by 33
Mechanisms of STAT3 activation in the liver of FXR knockout mice
Li, G., Zhu, Y., Tawfik, O. W., Kong, B., Williams, J. A. R., Zhan, L., Kassel, K. M., Luyendyk, J. P., Wang, L., & Guo, G. L. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00155.2013 · Cited by 36
Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach
Mousa, H. S., Carbone, M., Malinverno, F., Ronca, V., Gershwin, M. E., & Invernizzi, P. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.07.003 · Cited by 33
Oxysterols and Gastrointestinal Cancers Around the Clock
Kovač, U., Skubic, C., Bohinc, L., Rozman, D., & Režen, T. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00483 · Cited by 36
Increased hepatocellular carcinoma risk in chronic hepatitis B patients with persistently elevated serum total bile acid: a retrospective cohort study
Wang, H., Shang, X., Wan, X., Xiang, X., Mao, Q., Deng, G., & Wu, Y. (2016) · Scientific Reports · doi:10.1038/srep38180 · Cited by 32
Xanthohumol ameliorates Diet-Induced Liver Dysfunction via Farnesoid X Receptor-Dependent and Independent Signaling
Paraiso, I. L., Tran, T. Q., Magaña, A. A., Kundu, P., Choi, J., Maier, C. S., Bobe, G., Raber, J., Kioussi, C., & Stevens, J. F. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.643857 · Cited by 31
Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives
Macı́as, R. I. R. (2014) · ISRN Hepatology · doi:10.1155/2014/828074 · Cited by 32
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist
Epifano, F., Genovese, S., Squires, E. J., & Gray, M. A. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.03.057 · Cited by 32
Clustering Nuclear Receptors in Liver Regeneration Identifies Candidate Modulators of Hepatocyte Proliferation and Hepatocarcinoma
Vacca, M., D’Amore, S., Graziano, G., D’Orazio, A., Cariello, M., Massafra, V., Salvatore, L., Martelli, N., Murzilli, S., Sasso, G. L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104449 · Cited by 31
Secondary Unconjugated Bile Acids Induce Hepatic Stellate Cell Activation
Saga, K., Iwashita, Y., Hidano, S., Aso, Y., Isaka, K., Kido, Y., Tada, K., Takayama, H., Masuda, T., Hirashita, T., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103043 · Cited by 35
Inflammation-Related Carcinogenesis: Lessons from Animal Models to Clinical Aspects
Okada, F., Izutsu, R., Goto, K., & Osaki, M. (2021) · Cancers · doi:10.3390/cancers13040921 · Cited by 36
Sodium taurocholate inhibits intestinal adenoma formation in APCMin/+ mice, potentially through activation of the farnesoid X receptor
Smith, D. L. H., Keshavan, P., Avissar, U., Ahmed, K., & Zucker, S. D. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq050 · Cited by 31
Genetic polymorphism and variability of chemical carcinogenesis
Belitsky, G. A., & Геннадиевна, Я. М. (2008) · Biochemistry (Moscow) · doi:10.1134/s0006297908050076 · Cited by 31
Pleiotropic roles of FXR in liver and colorectal cancers
Huang, X., Fan, M., & Huang, W. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111543 · Cited by 32
Synthesis and evaluation of 18F-labeled bile acid compound: A potential PET imaging agent for FXR-related diseases
Jia, L., Jiang, D., Hu, P., Li, X., Shi, H., Cheng, D., & Zhang, L. (2014) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2014.03.016 · Cited by 30
FXR Agonists: From Bench to Bedside, a Guide for Clinicians
Alawad, A., & Levy, C. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4334-8 · Cited by 25
Genetics in Familial Intrahepatic Cholestasis: Clinical Patterns and Development of Liver and Biliary Cancers: A Review of the Literature
Vitale, G., Mattiaccio, A., Conti, A., Turco, L., Seri, M., Piscaglia, F., & Morelli, M. C. (2022) · Cancers · doi:10.3390/cancers14143421 · Cited by 30
Inhibition of leydig tumor growth by farnesoid X receptor activation: The in vitro and in vivo basis for a novel therapeutic strategy
Catalano, S., Panza, S., Malivindi, R., Giordano, C., Barone, I., Bossi, G., Lanzino, M., Sirianni, R., Mauro, L., Sisci, D., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27915 · Cited by 30
Deletion of IFNγ enhances hepatocarcinogenesis in FXR knockout mice
Meng, Z.-P., Wang, X.-Q., Gan, Y., Zhang, Y., Zhou, H., van Ness, C., Wu, J., Lou, G., Yu, H., He, C., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.016 · Cited by 26
FXR agonists enhance the sensitivity of biliary tract cancer cells to cisplatin via SHP dependent inhibition of Bcl-xL expression
Wang, W., Zhan, M., Li, Q., Chen, W., Chu, H., Huang, Q., Hou, Z., Man, M., & Wang, J. (2016) · Oncotarget · doi:10.18632/oncotarget.8964 · Cited by 30

Authors: Kim, I., Morimura, K., Shah, Y., Yang, Q., Ward, J. M., & Gonzalez, F. J.
Affiliations: National Institutes of Health (US)
Corresponding author: Gonzalez, Frank J.
ORCID: Shah, Yatrik
Yang, Qian
Ward, Jerrold M.
Gonzalez, Frank J.
Venue: Carcinogenesis
Publisher: Oxford University Press (OUP)
Published: 2006-12-20
Volume: 28
Issue: 5
Pages: 940-946
ISSN: 0143-3334 (ISSN-L)
1460-2180
DOI: 10.1093/carcin/bgl249
PMC: PMC1858639
OpenAlex: W2166661344
Cited by: 357
References: 38
Citations by year: 2026: 6 · 2025: 20 · 2024: 19 · 2023: 19 · 2022: 24 · 2021: 18 · 2020: 13 · 2019: 12 · 2018: 19 · 2017: 26 · 2016: 20 · 2015: 19 · 2014: 22 · 2013: 21 · 2012: 27
FWCI: 6.24
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Carcinogenesis (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Cancer Institute (Z01BC005708)
Topics: Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
Keywords: farnesoid X receptor, hepatocarcinogenesis, bile acids, bile acid pool size, liver tumors, hepatocellular carcinoma, hepatocellular adenoma, IL-1β, β-catenin, c-Myc, cell proliferation, PCNA, BrdU incorporation
MeSH terms: Receptor, Farnesoid X-Activated, Animals, Bile Acids and Salts, Biological Transport, Cell Transformation, Neoplastic, DNA-Binding Proteins, Female, Carcinoma, Hepatocellular, Inflammation, Liver, Liver Neoplasms, Male, Mice, Mutant Strains, Transcription Factors, Gene Expression, Receptors, Cytoplasmic and Nuclear, Adenoma, Liver Cell, Cholangiocarcinoma, Cell Proliferation, beta Catenin, Mice, Interleukin-1beta

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks